share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4:持股變動聲明-高管 Gibson Christopher
美股SEC公告 ·  08/28 16:18

Moomoo AI 已提取核心訊息

Recursion Pharmaceuticals CEO Christopher Gibson acquired 5,000 shares of the company's common stock on 08/28/2024. The transaction was executed at a price of $2.48 per share, reflecting a total investment of $12,400. Following this purchase, Gibson's direct holdings in Recursion Pharmaceuticals increased to 752,656 shares. The transaction, which is currently in progress, was reported as an exercise or conversion of derivative security, indicating a potential increase in the executive's confidence in the company's future prospects.
Recursion Pharmaceuticals CEO Christopher Gibson acquired 5,000 shares of the company's common stock on 08/28/2024. The transaction was executed at a price of $2.48 per share, reflecting a total investment of $12,400. Following this purchase, Gibson's direct holdings in Recursion Pharmaceuticals increased to 752,656 shares. The transaction, which is currently in progress, was reported as an exercise or conversion of derivative security, indicating a potential increase in the executive's confidence in the company's future prospects.
Recursion Pharmaceuticals首席執行官Christopher Gibson於08/28/2024購入了公司普通股5,000股。交易價格爲每股2.48美元,總投資額爲12,400美元。此次購買後,Gibson在Recursion Pharmaceuticals的直接持股增至752,656股。這筆交易目前正在進行中,被報告爲衍生安全轉換交易,表明執行官對公司未來前景的信心可能有所增強。
Recursion Pharmaceuticals首席執行官Christopher Gibson於08/28/2024購入了公司普通股5,000股。交易價格爲每股2.48美元,總投資額爲12,400美元。此次購買後,Gibson在Recursion Pharmaceuticals的直接持股增至752,656股。這筆交易目前正在進行中,被報告爲衍生安全轉換交易,表明執行官對公司未來前景的信心可能有所增強。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息